Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Lon...
Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States
About this item
Full title
Author / Creator
Publisher
New Zealand: Dove Medical Press Limited
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Dove Medical Press Limited
Subjects
More information
Scope and Contents
Contents
To evaluate the safety and tolerability of rimegepant 75 mg for the acute treatment of migraine in participants concurrently using a preventive migraine medication.
This long-term, open-label safety study (NCT03266588) enrolled adults with a history of 2-14 moderate or severe migraine attacks per month. Participants self-administered rimegepant...
Alternative Titles
Full title
Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_bad50ebe6cc344bc8143ce062d5bf55e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_bad50ebe6cc344bc8143ce062d5bf55e
Other Identifiers
ISSN
1178-7090
E-ISSN
1178-7090
DOI
10.2147/JPR.S453937
